These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2759729)

  • 41. 4- and 6-(p-Sulphamoylphenyl)androstenediones: Studies of aromatase inhibitor-based oestrone sulphatase inhibition.
    Watari Y; Yamaguchi S; Takahashi M; Nagaoka M; Numazawa M
    Steroids; 2010 Dec; 75(12):891-6. PubMed ID: 20546769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of treatment with 4-hydroxyandrostenedione or medroxyprogesterone acetate on human breast tumour regression.
    Coldham NG; Lai LC; Ghilchik MW; Walker MM; James VH; Reed MJ
    Anticancer Res; 1993; 13(3):753-8. PubMed ID: 8317908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oestrone sulphate, adipose tissue, and breast cancer.
    Hawkins RA; Thomson ML; Killen E
    Breast Cancer Res Treat; 1985; 6(1):75-87. PubMed ID: 4052635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relation between plasma androstenedione, plasma oestrone and androstenedione to oestrone conversion rates in post-menopausal women with and without fractures.
    Pelc B; Marshall DH; Guha P; Khan MY; Nordin BE
    Clin Sci Mol Med; 1978 Feb; 54(2):125-31. PubMed ID: 620501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of oestrone sulphatase activity in breast cancer cell lines by growth factors.
    Purohit A; Chapman O; Duncan L; Reed MJ
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):563-6. PubMed ID: 1562528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oestrogen synthesis by the peri-implantation conceptus of the one-humped camel (Camelus dromedarius).
    Skidmore JA; Allen WR; Heap RB
    J Reprod Fertil; 1994 Jul; 101(2):363-7. PubMed ID: 7932370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
    Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
    J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolism of 19-hydroxyandrostenedione in human subjects. Urinary excretion of conjugates.
    Kelly WG; de Leon O; Rizkallah TH
    J Clin Endocrinol Metab; 1978 Mar; 46(3):445-51. PubMed ID: 752031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 4-hydroxyandrostenedione--further clinical and extended endocrine observations.
    Pickles T; Perry L; Murray P; Plowman P
    Br J Cancer; 1990 Aug; 62(2):309-13. PubMed ID: 2386749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
    Purohit A; Ghilchik MW; Leese MP; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):167-72. PubMed ID: 15862962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of nonradiolabelled steroid infusions to investigate the origin of oestrone sulphate in postmenopausal women.
    Reed MJ; Noel CT; Jones DL; Jacobs HS; Scanlon MJ; James VH
    Horm Metab Res; 1986 Nov; 18(11):779-83. PubMed ID: 3792998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women.
    Reed MJ; Beranek PA; Bonney RC; Ghilchik MW; James VH
    Anticancer Res; 1987; 7(6):1265-9. PubMed ID: 2831795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accumulation of intermediates and isotopically sensitive enolization distinguish between aromatase (cytochrome P450 CYP19) from rat ovary and human placenta.
    Swinney DC; Watson DM; So OY
    Arch Biochem Biophys; 1993 Aug; 305(1):61-7. PubMed ID: 8342956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oestrogen formation in breast: clinical and biological importance.
    Dowsett M; Detre S; Rowlands M; Grimshaw R
    J Endocrinol; 1996 Sep; 150 Suppl():S59-63. PubMed ID: 8943788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
    Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A
    Lancet; 1984 Dec; 2(8414):1237-9. PubMed ID: 6150277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue].
    Utsumi T
    Nihon Geka Gakkai Zasshi; 1989 Jun; 90(6):920-7. PubMed ID: 2796962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
    Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
    Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL
    Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis.
    Coombes RC; Wilkinson JR; Bliss JM; Shah P; Easton DF; Dowsett M
    Br J Cancer; 1991 Aug; 64(2):247-50. PubMed ID: 1892751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.